A bio-inspired convolution neural network architecture for automatic breast cancer detection and classification using RNA-Seq gene expression data

Advancing breast ultrasound diagnostics through hybrid deep learning models

Today, doctors rely heavily on medical imaging to identify abnormalities. Proper classification of these abnormalities enables them to take informed actions, leading to early diagnosis and treatment. This paper introduces the "EfficientKNN" model, a novel hybrid deep learning approach that combines the advanced feature extraction capabilities of EfficientNetB3 with the simplicity and effectiveness of the k-Nearest Neighbors (k-NN) algorithm. Initially, EfficientNetB3, pre-trained on ImageNet, is repurposed to serve as a feature extractor. Subsequently, a GlobalAveragePooling2D layer is applied, followed by an optional Principal Component Analysis (PCA) to reduce dimensionality while preserving critical information. PCA is used selectively when deemed necessary. The extracted features are then classified using an optimized k-NN algorithm, fine-tuned through meticulous cross-validation.Our model underwent rigorous training using a curated dataset containing benign, malignant, and normal medical images. Data augmentation techniques, including rotations, shifts, flips, and zooms, were employed to help the model generalize and efficiently handle new, unseen data. To enhance the model's ability to identify the important features necessary for accurate predictions, the dataset was refined using segmentation and overlay techniques. The training utilized an ensemble of optimization algorithms-SGD, Adam, and RMSprop-with hyperparameters set at a learning rate of 0.00045, a batch size of 32, and up to 120 epochs, facilitated by early stopping to prevent overfitting.The results demonstrate that the EfficientKNN model outperforms traditional models such as VGG16, AlexNet, and VGG19 in terms of accuracy, precision, and F1-score. Additionally, the model showed better results compared to EfficientNetB3 alone. Achieving a 100 % accuracy rate on multiple tests, the EfficientKNN model has significant potential for real-world diagnostic applications. This study highlights the model's scalability, efficient use of cloud storage, and real-time prediction capabilities, all while minimizing computational demands.By integrating the strengths of EfficientNetB3's deep learning architecture with the interpretability of k-NN, EfficientKNN presents a significant advancement in medical image classification, promising improved diagnostic accuracy and clinical applicability.

Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach

Breast cancer remains a major public health challenge worldwide. The identification of accurate biomarkers is critical for the early detection and effective treatment of breast cancer. This study utilizes an integrative machine learning approach to analyze breast cancer gene expression data for superior biomarker and drug target discovery. Gene expression datasets, obtained from the GEO database, were merged post-preprocessing. From the merged dataset, differential expression analysis between breast cancer and normal samples revealed 164 differentially expressed genes. Meanwhile, a separate gene expression dataset revealed 350 differentially expressed genes. Additionally, the BGWO_SA_Ens algorithm, integrating binary grey wolf optimization and simulated annealing with an ensemble classifier, was employed on gene expression datasets to identify predictive genes including TOP2A, AKR1C3, EZH2, MMP1, EDNRB, S100B, and SPP1. From over 10,000 genes, BGWO_SA_Ens identified 1404 in the merged dataset (F1 score: 0.981, PR-AUC: 0.998, ROC-AUC: 0.995) and 1710 in the GSE45827 dataset (F1 score: 0.965, PR-AUC: 0.986, ROC-AUC: 0.972). The intersection of DEGs and BGWO_SA_Ens selected genes revealed 35 superior genes that were consistently significant across methods. Enrichment analyses uncovered the involvement of these superior genes in key pathways such as AMPK, Adipocytokine, and PPAR signaling. Protein-protein interaction network analysis highlighted subnetworks and central nodes. Finally, a drug-gene interaction investigation revealed connections between superior genes and anticancer drugs. Collectively, the machine learning workflow identified a robust gene signature for breast cancer, illuminated their biological roles, interactions and therapeutic associations, and underscored the potential of computational approaches in biomarker discovery and precision oncology.

Artificial Intelligence for the Management of Breast Cancer: An Overview

Breast cancer is a severe global health problem, and early detection, accurate diagnosis, and personalized treatment is the key to improving patient outcomes. Artificial intelligence (AI) and machine learning (ML) have emerged as promising breast cancer research and clinical practice tools in recent years. Various projects are underway in early detection, diagnosis, prognosis, drug discovery, advanced image analysis, precision medicine, predictive modeling, and personalized treatment planning using artificial intelligence and machine learning. These projects use different algorithms, including convolutional neural networks (CNNs), support vector machines (SVMs), decision trees, and deep learning methods, to analyze and improve different types of data, such as clinical, genomic, and imaging data for breast cancer management. The success of these projects has the potential to transform breast cancer care, and continued research and development in this area is likely to lead to more accurate and personalized breast cancer diagnosis, treatment, and outcomes.